Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q4 CY2024, ...

We recently published a list of Jim Cramer Breaks Silence On DeepSeek AI Sell-Off & Discusses These 12 Stocks. In this ...

A product made in Columbus reached a major milestone at the end of 2024. Ensure, a nutritional drink made by Abbott ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics ...

Investment analysts at William Blair dropped their Q1 2025 earnings estimates for shares of Abbott Laboratories in a report ...

In a report released yesterday, David Toung from Argus Research maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The ...

Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...

Abbott Laboratories (NYSE:ABT – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Barclays in a report released on Monday, MarketBeat reports. They currently ...

During this period, the Zacks Medical - Products industry, which Abbott falls in, has gained 9.7%. The key question now is: What could be the stock's future direction? While media releases or ...